March 20, 2026
MyOme Demonstrates Clinical Validity of Integrated Polygenic and Clinical Risk Prediction for Coronary Artery Disease
New MyOme findings show that integrating polygenic scores with clinical risk factors can provide more precise and stable coronary artery disease risk prediction.
March 12, 2026
MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
MyOme announced an advancement in rare disease diagnostics at ACMG 2026, including a strategic partnership with Natera and launch of long-read methylation analysis.
December 15, 2025
Thatch and MyOme Launch First Genomics Solution in Thatch's Personalized Benefits Marketplace
This collaboration will embed MyOme's genomics-based proactive health reports into the Thatch Marketplace, providing members with easier access to cutting-edge health insights.
December 14, 2025
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.
December 3, 2025
MyOme and Ms.Medicine Announce Strategic Partnership to Redefine Personalized Primary Care Through Genomics
Together, the organizations are pioneering a new model for primary care —one where comprehensive, proactive genomic insights are seamlessly integrated into everyday patient care.
November 20, 2025
MyOme Launches First Integrated Polygenic Risk Score for Prostate Cancer to Advance Early Detection and Personalized Prevention
New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men.
November 6, 2025
MyOme Launches Proactive Health Network — A First-of-Its-Kind National Platform for Concierge & Executive Health Clinics Powered by Whole-Genome Precision
MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Proactive Health Network (PHN) — a new national ecosystem uniting top concierge, executive health and longevity-focused clinics under a shared mission: to shift medicine from reactive disease treatment to proactive, personalized health management at scale.
September 18, 2025
MyOme Expands Rare Disease Test with New Genome Insights
MyOme, Inc., a leading genomics innovation company, today announced the expansion of its rare disease test to include tandem repeat expansions (TREs) and mitochondrial genome analyses.
September 3, 2025
MyOme Expands Proactive Health Portfolio with Launch of Type 2 Diabetes Integrated Polygenic Risk Score (iPRS)™
MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) Integrated Polygenic Risk Score™ (iPRS).
August 12, 2025
MyOme Joins Mayo Clinic Platform_Accelerate Cohort to Advance Preventative Care
MyOme, Inc., a leader in whole-genome analysis and polygenic risk scores, today announced its entry into Mayo Clinic Platform_Accelerate, an initiative that supports healthcare innovators to validate and scale artificial intelligence (AI) based solutions using rich, de-identified clinical data sets.
May 7, 2025
MyOme and Collective Health® Partner to Expand Access to MyOme's Whole-Genome Based Products for Employers
MyOme, Inc., a leading whole-genome analysis and polygenic risk modeling (PRS) company, announced that it has joined The Partner Collective® by Collective Health®— a digital health partner hub that helps employers, brokers, and consultants discover and engage with innovative benefits offerings.
March 19, 2025
MyOme Launches their Rare Disease Product Portfolio at ACMG 2025
MyOme, Inc., a leader in clinical whole-genome analysis and polygenic risk scores, is pleased to announce the launch of its rare disease diagnostic offering at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting on March 19, 2025.
February 27, 2025
MyOme Announces Launch of CAD iPRS and Beginning Enrollment in the COMPASS-CAD Prospective Trial
MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery disease (CAD) PRS product – Integrated PRS, CAD (CAD iPRS)
January 30, 2025
MyOme and Novi Health Collaborate to Bring Whole Genome Testing to Employer Health Programs
MyOme has partnered with Novi Health to bring whole genome sequencing, polygenic risk modeling, and personalized genetic counseling to employees as part of workplace health benefits, empowering participants to take preventative action against common and hereditary conditions.
December 9, 2024
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test …
October 14, 2024
MyOme and Broad Clinical Labs to Support Southern Research Program to Bring Genetics-Driven Health Insights to Alabamians Free of Charge
Initiative to Empower the Underserved Community of Patients and Providers with Access to Personal Health Risks and Actionable Information to Prevent or Treat Disease…
November 2, 2023
MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting
Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals…
March 16, 2023
MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting
Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical…
February 22, 2023
MyOme, Natera Show Cross-Ancestry Polygenic Risk Score Improves Breast Cancer Prediction -GenomeWeb
From GenomeWeb: 'NEW YORK – Personalized genomics company MyOme's cross-ancestry, integrated risk score (caIRS) improved breast cancer prediction over the standard Tyrer-Cuzick (T-C) model…'
February 22, 2023
MyOme Announces Publication of a Validated Cross-Ancestry Polygenic Risk Score for Breast Cancer
Data demonstrates improved breast cancer risk prediction across multiple ancestries over standard of care…
October 27, 2022
MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment
Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries…
June 21, 2022
MyOme Secures $23M in Series B Funding to Deliver Clinical Whole Genome Insights to Help Families Manage Risk for Inherited Diseases
The oversubscribed series B financing led by Healthcare Venture Partners, added SoftBank Corp. and Natera to existing investors– Sequoia Capital, Foresite Capital, Founders Fund, …
June 16, 2022
Equity Issues, Admixed Populations Continue to Complicate Use of Polygenic Risk Scores — GenomeWeb
A dearth of genome-wide association studies focused on non-European populations, plus issues related to applying polygenic risk scores in populations with multiple ancestries, has spurred…
June 15, 2022
MyOme Develops Cross-Ancestry Breast Cancer Polygenic Risk Score, Plans Product Launch — GenomeWeb
NEW YORK – Personalized genomics company MyOme presented data at the recent American Society of Clinical Oncology conference demonstrating its ability to train and validate…
June 1, 2022
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast Cancer
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast CancerStudy highlights potential of Polygenic Risk Scores (PRS) to improve breast…
April 6, 2022
Is it time to test embryos for common diseases? — MedicalXpress.com
A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes…